Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.05
-$0.07-6.25%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 315.38% | 805.71% | -35.14% | 100.00% | 69.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 315.38% | 805.71% | -35.14% | 100.00% | 69.57% |
| Cost of Revenue | 66.38% | 8.93% | -19.43% | -15.28% | -32.68% |
| Gross Profit | -65.46% | -6.84% | 19.39% | 15.38% | 32.83% |
| SG&A Expenses | 156.25% | 180.82% | 125.42% | 84.59% | 72.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.24% | 85.33% | 33.09% | 19.58% | 0.65% |
| Operating Income | -114.90% | -84.28% | -33.20% | -19.53% | -0.58% |
| Income Before Tax | -116.04% | -82.63% | -36.03% | -19.07% | -1.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -116.04% | -82.63% | -36.03% | -19.07% | -1.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.04% | -82.63% | -36.03% | -19.07% | -1.15% |
| EBIT | -114.90% | -84.28% | -33.20% | -19.53% | -0.58% |
| EBITDA | -115.25% | -84.50% | -33.34% | -19.66% | -0.55% |
| EPS Basic | -54.30% | -33.48% | -7.37% | 6.05% | 15.70% |
| Normalized Basic EPS | -54.19% | -33.40% | -7.32% | 6.05% | 15.64% |
| EPS Diluted | -54.30% | -33.48% | -7.37% | 6.05% | 15.70% |
| Normalized Diluted EPS | -54.19% | -33.40% | -7.32% | 6.05% | 15.64% |
| Average Basic Shares Outstanding | 40.03% | 36.87% | 26.73% | 26.75% | 19.95% |
| Average Diluted Shares Outstanding | 40.03% | 36.87% | 26.73% | 26.75% | 19.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |